By Fineline Cube 
China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that its holding subsidiary Neurovita has received market approval from the National Medical Products Administration (NMPA) for its AUCURA flow-diverting stent. This approval is for the treatment of adult patients with ruptured cystic or fusiform wide neck aneurysms (neck width ≥ 4mm or tumor/neck ratio < 2) of the internal carotid artery (from the petrous segment to the distal end) and vertebral artery, with a diameter of the tumor-carrying vessel ranging from 2.0mm to 6.0mm.
Product Innovation and Features
AUCURA represents China’s first flow-diverting stent featuring both 0.017-inch system deliverability and an antithrombotic coating. The stent is woven from cobalt-chromium-platinum DFT wire with full-body radiopacity. Its superhydrophilic surface technology reduces contact angle to minimize plasma protein/platelet adhesion, significantly lowering the risk of stent thrombosis. By modifying aneurysm hemodynamics and promoting endothelial healing at the neck region, AUCURA enables effective treatment of intracranial aneurysms.-Fineline Info & Tech